Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07182422 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease

Study acronym: ASTRA-AKD
StatusRecruiting
PhasePhase 4
Started2025-09-15
View on ClinicalTrials.gov ↗
The primary goal of this clinical trial is to evaluate the efficacy of AST-120 (Kremezin®) in combination with standard care in reducing the levels of protein-bound uremic toxins (PBUTs), specifically indoxyl sulfate (IS) and p-cresyl sulfate (p-CS), in patients with acute kidney disease (AKD). The trial aims to assess whether AST-120 can prevent further renal deterioration and slow the progression from AKD to chronic kidney disease (CKD) by mitigating the accumulation of PBUTs. Additionally, the study will investigate the potential of AST-120 to reduce the risk of CKD-associated complications, including cardiovascular disease, by reducing PBUT levels in AKD patients.
Trial Details
NCT Number NCT07182422
Lead Sponsor Chang Gung Memorial Hospital
Collaborators: Conmed Pharmaceutical & Bio-Medical Corporation
Conditions Acute Kidney Disease, Acute Kidney Injury (AKI)
Enrollment 100 participants
Start Date 2025-09-15
Primary Completion 2027-02-11 (estimated)
Study Completion 2027-03-13 (estimated)
Updated on ClinicalTrials.gov 2025-09-19